A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 (NSC 716051) in Combination With Interferon-Alpha in Patients With Chronic Myelogenous Leukemia in Chronic Phase.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary) ; Interferon alpha
Indications Chronic myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Jun 2011 Planned end date (May 2011) added as reported by ClinicalTrials.gov.
17 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
28 Feb 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight